Literature DB >> 27856191

Avoiding phagocytosis-related artifact in myeloid derived suppressor cell T-lymphocyte suppression assays.

Ruth J Davis1, Christopher Silvin1, Clint T Allen2.   

Abstract

Myeloid-derived suppressor cells (MDSCs) have garnered much attention in recent years as a potential target for altering the immunosuppressive tumor microenvironment in a variety of solid tumor types. The ability to accurately assess the immunosuppressive capacity of MDSCs is fundamental to the development of therapeutic approaches aimed at disabling these immunosuppressive functions. In this article we provide evidence that the use of CD3/28 coated microbeads leads to artefactual T-lymphocyte suppression due to sequestration of beads by MDSCs isolated from the spleens of wild-type mice bearing subcutaneous syngeneic, carcinogen-induced oral cavity carcinomas. Mechanisms of this finding may include early MDSC death and acquisition of phagocytic capacity. These artefactual findings were avoided by eliminating the use of microbeads and instead using plate bound CD3/28 antibody as the T-lymphocyte stimulus. We propose model-specific validation of microbead-based MDSC assays, or use of an alternative stimulation approach such as plate bound CD3/28 antibodies.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Artifact; CD3/28 microbeads; MDSC; Myeloid-derived suppressor cells; Phagocytosis; T-cell suppression assay

Mesh:

Substances:

Year:  2016        PMID: 27856191      PMCID: PMC5186333          DOI: 10.1016/j.jim.2016.11.006

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  19 in total

1.  Suppression of CD3/CD28 antibody stimulated responses by human granulocytic myeloid-derived suppressor cells: fact or artefact?

Authors:  Barry D Hock; Judith L McKenzie
Journal:  Immunol Lett       Date:  2013-05-30       Impact factor: 3.685

2.  Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.

Authors:  Steven L Highfill; Yongzhi Cui; Amber J Giles; Jillian P Smith; Hua Zhang; Elizabeth Morse; Rosandra N Kaplan; Crystal L Mackall
Journal:  Sci Transl Med       Date:  2014-05-21       Impact factor: 17.956

3.  Effect of activated human polymorphonuclear leucocytes on T lymphocyte proliferation and viability.

Authors:  Barry D Hock; Karen G Taylor; Nicholas B Cross; Anthony J Kettle; Mark B Hampton; Judith L McKenzie
Journal:  Immunology       Date:  2012-11       Impact factor: 7.397

4.  Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.

Authors:  Rachel F Gabitass; Nicola E Annels; Deborah D Stocken; Hardev A Pandha; Gary W Middleton
Journal:  Cancer Immunol Immunother       Date:  2011-06-05       Impact factor: 6.968

5.  Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism.

Authors:  Siqi Chen; Long Wang; Jie Fan; Cong Ye; Donye Dominguez; Yi Zhang; Tyler J Curiel; Deyu Fang; Timothy M Kuzel; Bin Zhang
Journal:  Cancer Res       Date:  2014-12-10       Impact factor: 12.701

6.  Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma.

Authors:  Donald T Weed; Paolo Serafini; Jennifer L Vella; Isildinha M Reis; Adriana C De la Fuente; Carmen Gomez; Zoukaa Sargi; Ronen Nazarian; Joseph Califano; Ivan Borrello
Journal:  Clin Cancer Res       Date:  2014-10-15       Impact factor: 12.531

Review 7.  Functional variability of antibodies upon oxidative processes.

Authors:  Jordan D Dimitrov; Tchavdar L Vassilev; Sebastien Andre; Srinivas V Kaveri; Sebastien Lacroix-Desmazes
Journal:  Autoimmun Rev       Date:  2008-05-01       Impact factor: 9.754

8.  Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor.

Authors:  A S Pak; M A Wright; J P Matthews; S L Collins; G J Petruzzelli; M R Young
Journal:  Clin Cancer Res       Date:  1995-01       Impact factor: 12.531

Review 9.  Myeloid-derived suppressor cells as regulators of the immune system.

Authors:  Dmitry I Gabrilovich; Srinivas Nagaraj
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

10.  mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer.

Authors:  Harrison Cash; Sujay Shah; Ellen Moore; Andria Caruso; Ravindra Uppaluri; Carter Van Waes; Clint Allen
Journal:  Oncotarget       Date:  2015-11-03
View more
  10 in total

1.  Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function.

Authors:  Paul E Clavijo; Jay Friedman; Yvette Robbins; Ellen C Moore; Ernest Smith; Maurice Zauderer; Elizabeth E Evans; Clint T Allen
Journal:  Cancer Immunol Res       Date:  2018-12-04       Impact factor: 11.151

2.  Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer.

Authors:  Roy Xiao; Clint T Allen; Linda Tran; Priya Patel; So-Jin Park; Zhong Chen; Carter Van Waes; Nicole C Schmitt
Journal:  Oncoimmunology       Date:  2018-08-01       Impact factor: 8.110

3.  Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.

Authors:  Lillian Sun; Paul E Clavijo; Yvette Robbins; Priya Patel; Jay Friedman; Sarah Greene; Rita Das; Chris Silvin; Carter Van Waes; Lucas A Horn; Jeffrey Schlom; Claudia Palena; Dean Maeda; John Zebala; Clint T Allen
Journal:  JCI Insight       Date:  2019-04-04

4.  Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.

Authors:  Sarah Greene; Yvette Robbins; Wojciech K Mydlarz; Angel P Huynh; Nicole C Schmitt; Jay Friedman; Lucas A Horn; Claudia Palena; Jeffrey Schlom; Dean Y Maeda; John A Zebala; Paul E Clavijo; Clint Allen
Journal:  Clin Cancer Res       Date:  2019-12-17       Impact factor: 12.531

5.  Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ.

Authors:  Ruth J Davis; Ellen C Moore; Paul E Clavijo; Jay Friedman; Harrison Cash; Zhong Chen; Chris Silvin; Carter Van Waes; Clint Allen
Journal:  Cancer Res       Date:  2017-03-31       Impact factor: 12.701

6.  Dose-dependent enhancement of T-lymphocyte priming and CTL lysis following ionizing radiation in an engineered model of oral cancer.

Authors:  Megan Morisada; Ellen C Moore; Rachel Hodge; Jay Friedman; Harrison A Cash; James W Hodge; James B Mitchell; Clint T Allen
Journal:  Oral Oncol       Date:  2017-06-10       Impact factor: 5.337

7.  Lactoferrin-induced myeloid-derived suppressor cell therapy attenuates pathologic inflammatory conditions in newborn mice.

Authors:  Yufeng Liu; Michela Perego; Qiang Xiao; Yumei He; Shuyu Fu; Juan He; Wangkai Liu; Xing Li; Yanlai Tang; Xiaoyu Li; Weiming Yuan; Wei Zhou; Fan Wu; Chunhong Jia; Qiliang Cui; George S Worthen; Erik A Jensen; Dmitry I Gabrilovich; Jie Zhou
Journal:  J Clin Invest       Date:  2019-10-01       Impact factor: 19.456

8.  Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells.

Authors:  Paul E Clavijo; Ellen C Moore; Jianhong Chen; Ruth J Davis; Jay Friedman; Young Kim; Carter Van Waes; Zhong Chen; Clint T Allen
Journal:  Oncotarget       Date:  2017-06-11

Review 9.  Neutrophil Maturity in Cancer.

Authors:  John B G Mackey; Seth B Coffelt; Leo M Carlin
Journal:  Front Immunol       Date:  2019-08-14       Impact factor: 7.561

10.  Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity.

Authors:  Youji Hong; Yvette Robbins; Xinping Yang; Wojciech K Mydlarz; Anastasia Sowers; James B Mitchell; James L Gulley; Jeffrey Schlom; Sofia R Gameiro; Cem Sievers; Clint T Allen
Journal:  JCI Insight       Date:  2022-03-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.